{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:22:07Z","timestamp":1778617327596,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["R-154-000-697-112"],"award-info":[{"award-number":["R-154-000-697-112"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["R154-000-A72114"],"award-info":[{"award-number":["R154-000-A72114"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["R-154-000-B03-112"],"award-info":[{"award-number":["R-154-000-B03-112"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.it.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T18:30:06Z","timestamp":1600367406000},"page":"1006-1022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions"],"prefix":"10.1016","volume":"41","author":[{"given":"Edem","family":"Gavor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeu Khai","family":"Choong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi Yin","family":"Er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hariharan","family":"Sivaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sivaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2020.09.004_bb0005","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1073\/pnas.0506735102","article-title":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats","volume":"102","author":"Lau","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2020.09.004_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","article-title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor","volume":"503","author":"Ge","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0015","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2020.09.004_bb0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41586-020-2271-3","article-title":"Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals","volume":"582","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0030","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.11.2000285","article-title":"Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union\/European Economic Area and the United Kingdom, 1 January to 15 March 2020","volume":"25","author":"Kinross","year":"2020","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.it.2020.09.004_bb0035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.it.2020.09.004_bb0040","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2013 preliminary report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2020.09.004_bb0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2020.09.004_bb0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.it.2020.09.004_bb0055","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.it.2020.09.004_bb0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.it.2020.09.004_bb0065","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2020.09.004_bb0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2004.10.052","article-title":"Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry","volume":"325","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.it.2020.09.004_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0080","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.it.2020.09.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2020.07.004","article-title":"Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2","author":"Renn","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.it.2020.09.004_bb0090","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191663","article-title":"Challenges of CAR- and TCR-T cell-based therapy for chronic infections","volume":"217","author":"Bertoletti","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2020.09.004_bb0095","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2020.09.004_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","article-title":"Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans","volume":"27","author":"Rijal","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2020.09.004_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature\u2019s pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.it.2020.09.004_bb9000","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/cr.2015.34","article-title":"Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody","volume":"25","author":"Gu","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.it.2020.09.004_bb9005","doi-asserted-by":"crossref","first-page":"10266","DOI":"10.1073\/pnas.1101309108","article-title":"Structural basis for the neutralization and genotype specificity of hepatitis E virus","volume":"108","author":"Tang","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.it.2020.09.004_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.it.2020.09.004_bb0115","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.it.2020.09.004_bb0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.tim.2020.05.012","article-title":"Spiking pandemic potential: structural and immunological aspects of SARS-CoV-2","volume":"28","author":"Wang","year":"2020","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.it.2020.09.004_bb0125","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.it.2020.09.004_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0135","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.it.2020.09.004_bb0140","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.it.2020.09.004_bb0145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0150","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.it.2020.09.004_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0160","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2020.09.004_bb0165","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.it.2020.09.004_bb0170","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.it.2020.09.004_bb0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.09.004_bb0180","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.it.2020.09.004_bb0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.it.2020.09.004_bb0190","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.it.2020.09.004_bb0195","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.it.2020.09.004_bb0200","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.it.2020.09.004_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107918","article-title":"Human-IgG neutralizing monoclonal antibodies block the SARS-CoV-2 infection","volume":"32","author":"Wan","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2020.09.004_bb0210","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.it.2020.09.004_bb0215","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.it.2020.09.004_bb0220","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/22221751.2020.1768806","article-title":"Development of multi-specific humanized llama antibodies blocking SARS-CoV-2\/ACE2 interaction with high affinity and avidity","volume":"9","author":"Dong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.it.2020.09.004_bb0225","article-title":"An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking spike into an inactive conformation","author":"Schoof","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.it.2020.09.004_bb0230","article-title":"A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential","author":"Gai","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.it.2020.09.004_bb0235","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/ciu887","article-title":"Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys","volume":"60","author":"Sun","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.it.2020.09.004_bb0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","article-title":"Blockade of the C5a\u2013C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV article","volume":"7","author":"Jiang","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.it.2020.09.004_bb0245","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1038\/emi.2015.28","article-title":"The role of C5a in acute lung injury induced by highly pathogenic viral infections","volume":"4","author":"Wang","year":"2015","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.it.2020.09.004_bb0250","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"MBi."},{"key":"10.1016\/j.it.2020.09.004_bb0255","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.it.2020.09.004_bb0260","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.it.2020.09.004_bb0265","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.it.2020.09.004_bb0270","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/v12040360","article-title":"Structural genomics of SARS-COV-2 indicates evolutionary conserved functional regions of viral proteins","volume":"12","author":"Srinivasan","year":"2020","journal-title":"Viruses."},{"key":"10.1016\/j.it.2020.09.004_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2020.09.004_bb0280","article-title":"Structures, conformations and distributions of SARS-CoV-2 spike protein trimers on intact virions","author":"Ke","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.it.2020.09.004_bb0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.it.2020.09.004_bb0290","article-title":"Structural basis of SARS-CoV-2 and SARS-CoV-receptor binding and small-molecule blockers as potential therapeutics","author":"Sivaraman","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.it.2020.09.004_bb0295","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1371\/journal.pone.0000024","article-title":"Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus","volume":"1","author":"Li","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2020.09.004_bb0300","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1073\/pnas.0403492101","article-title":"Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity","volume":"101","author":"Buchholz","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2020.09.004_bb0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vaccine.2006.06.084","article-title":"Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine","volume":"25","author":"Zakhartchouk","year":"2007","journal-title":"Vaccine."},{"key":"10.1016\/j.it.2020.09.004_bb0310","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2020.09.004_bb0315","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(04)16501-X","article-title":"Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS","volume":"363","author":"Bukreyev","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.it.2020.09.004_bb0320","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","article-title":"Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets","volume":"23","author":"Czub","year":"2005","journal-title":"Vaccine."},{"key":"10.1016\/j.it.2020.09.004_bb0325","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2020.09.004_bb0330","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1128\/JVI.78.13.7217-7226.2004","article-title":"An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies","volume":"78","author":"Zhou","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2020.09.004_bb0335","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/JVI.79.6.3289-3296.2005","article-title":"Amino Acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents","volume":"79","author":"Keng","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2020.09.004_bb0340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2005.01.034","article-title":"Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines","volume":"334","author":"He","year":"2005","journal-title":"Virology."},{"key":"10.1016\/j.it.2020.09.004_bb0345","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fcimb.2018.00044","article-title":"Antibody-dependent enhancement and Zika: real threat or phantom menace?","volume":"8","author":"Mart\u00edn-Acebes","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.it.2020.09.004_bb0350","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2020.06.040","article-title":"Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear","volume":"182","author":"Grubaugh","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.it.2020.09.004_bb0360","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell."},{"key":"10.1016\/j.it.2020.09.004_bb0365","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.it.2020.09.004_bb0380","doi-asserted-by":"crossref","first-page":"34610","DOI":"10.1074\/jbc.M603275200","article-title":"Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R","volume":"281","author":"Hwang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2020.09.004_bb0385","doi-asserted-by":"crossref","first-page":"15829","DOI":"10.1074\/jbc.M600697200","article-title":"Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody","volume":"281","author":"Prabakaran","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2020.09.004_bb0390","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.4049\/jimmunol.176.10.6085","article-title":"Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein","volume":"176","author":"He","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2020.09.004_bb0395","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.it.2020.09.004_bb0400","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.it.2020.09.004_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","author":"Bournazos","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.it.2020.09.004_bb0410","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.it.2020.09.004_bb0415","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00431-018-03310-7","article-title":"New therapies for acute RSV infections: where are we?","volume":"178","author":"Xing","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.it.2020.09.004_bb0420","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1128\/JVI.02377-07","article-title":"Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge","volume":"82","author":"Rockx","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2020.09.004_bb0375","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2020.09.004_bb0430","doi-asserted-by":"crossref","DOI":"10.1038\/s41594-020-0480-y","article-title":"Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient","author":"Zhou","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.it.2020.09.004_bb0435","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.it.2020.09.004_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.it.2020.09.004_bb0450","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.it.2020.09.004_bb0455","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","article-title":"Neutralization of SARS-CoV-2 by destruction of the prefusion spike","volume":"28","author":"Jiandong Huo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.it.2020.09.004_bb0370","series-title":"A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV","first-page":"630","volume":"368","author":"Yuan","year":"2020"},{"key":"10.1016\/j.it.2020.09.004_bb0470","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.it.2020.09.004_bb0465","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"Ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.it.2020.09.004_bb0460","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490620302118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490620302118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:51:06Z","timestamp":1778615466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490620302118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1471490620302118"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2020.09.004","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}